Please assess the completion status of the following clinical trial:

Trial Title: Study of AC-201 in Patients With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Understanding of the study procedures and agreement to participate in the study by giving written informed consent~* Males and females age 20 to 75 years, inclusive~* HbA1c ≥7.5% and ≤10%~* BMI ≤45 kg/m2~* FPG ≤270 mg/dL~* Diagnosis of type 2 diabetes mellitus for ≥6 months~* On a stable regimen of oral anti-diabetic medications for ≥3 months~* Willingness to maintain stable diet and exercise throughout the study~* Willingness to maintain current doses/regimens of vitamins and dietary supplements throughout the study~* Female patients of childbearing potential and female partners of male patients must be willing to use adequate contraception during the study. All females of childbearing potential must have a negative urine pregnancy test at screening.~Exclusion Criteria:~* History of type 1 diabetes and/or history of ketoacidosis~* History of diabetic neuropathy resulting in significant functional impairment and/or requiring active medical or surgical management, including chronic pain syndromes, gastroparesis, skin ulceration, or amputation~* History of long-term therapy with insulin (\>30 days) within 1 year of screening;~* Pregnancy or lactation~* Current treatment with any of the following medications within 2 months of screening~* Anti inflammatory drugs, including chronic daily use of systemic corticosteroids (aspirin ≤325 mg per day is allowed)~* IL-1 modulators: anakinra and rilonacept~* Immunosuppressive drugs: TNF inhibitors and IL-6 monoclonal antibody~* History of severe hypoglycemic episodes within 6 months of screening~* Hypersensitivity to AC-201 or anthraquinone derivatives~* Surgery within 30 days prior to screening~* Serum creatinine \>1.5 mg/dL for males or \>1.4 mg/dL for females~* Presence of cancer or history of cancer within the past 5 years other than basal or squamous cell carcinoma of the skin and carcinoma in situ of the cervix~* Advanced stage heart failure: New York Heart Association Class III or IV cardiac status or hospitalization for congestive heart failure~* History of unstable angina, myocardial infarction, uncontrolled arrhythmias, cerebrovascular accident, transient ischemic attack, or any revascularization, including percutaneous transluminal coronary angioplasty, within 6 months of screening~* Uncontrolled hypertension (defined as systolic blood pressure \>160 mmHg or diastolic blood pressure \>100 mmHg on ≥3 assessments at screening)~* Known to be infected with human immunodeficiency virus (HIV)~* History of acquired immune deficiency syndrome~* History of TB, active TB (pulmonary, extra-pulmonary, or military), or a positive test for TB confirmed by a PA chest x-ray within 6 months prior to screening~* History of acute infection with Epstein-Barr Virus (EBV), cytomegalovirus (CMV), or hepatitis C virus (HCV) within 4 weeks prior to screening~* History of chronic active (not latent) hepatitis B virus, HCV, or CMV infection;~* History of drug or alcohol abuse~* Aspartate aminotransferase \>3 × the upper limit of normal (ULN) or alanine aminotransferase \>3 × ULN at screening~* Total bilirubin \>1.5 × ULN at screening~* Triglycerides \>500 mg/dL at screening~* Poor mental function or any other reason to expect patient difficulty in complying with the study requirements~* Acute infections that may affect blood glucose control within 4 weeks prior to screening~* Known bilateral renal artery stenosis, patient with a solitary kidney, or a post renal transplant~* History of autoimmune disease or collagen vascular disease~* History of hyperthyroidism or hypocorticism~* Participation in any AC-201 studies within 1 year prior to screening~* Participation in an investigational drug study within 30 days prior to screening~* Any other serious diseases which, in the opinion of the investigator, might pose a risk to the patient or make participation not in the patient's best interest.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- AC-201, 25mg (Type: EXPERIMENTAL): 25mg BID for 24 weeks
- AC-201, 50mg (Type: EXPERIMENTAL): 50mg BID for 24 weeks
- AC-201, 75mg (Type: EXPERIMENTAL): 75mg BID for 24 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo BID for 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete